Report on Operations 2021: Continuous growth and a new Vitrolife
Fourth quarter · Sales of SEK 514 (382) million, corresponding to an increase of 35 percent in SEK. Consumables increased by 9 percent, Genomics 33 percent, Technology decreased by 12 percent. The organic growth was 4 percent. · The acquisition of Igenomix was completed the last day of November and is included as division Genetic Services in December 2021. · Sales in Genetic Services, only for December, were SEK 116 million corresponding to an acquired growth of 30 percent. · Operating income before depreciation and amortization (EBITDA) was SEK 164 million, adjusted for non-